Every morning I open the same orange bottle, tap out a small white pill, and swallow it without ceremony. I'm 36. I have no symptoms. I haven't had a heart attack. My cardiologist hasn't referred me anywhere. I started this four years ago — not out of fear, but out of an honest accounting of the evidence.

My LDL in May 2018 was 127 mg/dL. I was 28 years old, apparently healthy, and no one in the room was particularly alarmed. By conventional thresholds, they shouldn't have been. But it wasn't where it needed to be — and, more importantly, I knew that the relevant question wasn't where I was at 28, but where my vascular biology would be at 60 if I didn't act.

Over the next two years my LDL fluctuated between 79 and 127 mg/dL — the kind of variation that looks unremarkable on a single visit, more meaningful over a trend. I started a statin in late 2021. My most recent value: 31 mg/dL.

As a physician, I've spent years counseling patients about statins. I've watched people stop them over muscle aches that turned out to be entirely independent of the drug. I've watched people avoid them because they feared dementia — a fear the RCT data has consistently failed to confirm. And I've watched cardiovascular events happen to people who, by all algorithmic logic, should have been on one.

Eventually, it felt disingenuous not to apply the same reasoning to myself.

What follows is my honest read of the evidence: what statins actually do in primary prevention, what they don't do, and why I think the risk-benefit calculation for a large portion of middle-aged adults has become, quietly, one of the clearest in all of preventive medicine.

The foundational data on statins for primary prevention comes from the Cholesterol Treatment Trialists' (CTT) Collaboration — the most comprehensive individual patient-level meta-analysis of statin therapy ever assembled. Across 27 randomized trials involving more than 170,000 participants, the CTT found that each 1 mmol/L (roughly 38.7 mg/dL) reduction in LDL cholesterol produced approximately a 21% relative reduction in major vascular events — heart attacks, strokes, and coronary revascularizations — regardless of baseline cardiovascular risk.

Crucially, this benefit was observed even in people at lower risk — people like me. The 2012 CTT analysis specifically examined individuals with a 5-year risk of major vascular events below 10%, and found approximately 11 fewer major vascular events per 1,000 people treated over 5 years per mmol/L of LDL lowered. That benefit, they argued, substantially exceeded any known harm from statin therapy.

A Cochrane systematic review of statins for primary prevention synthesized 18 randomized controlled trials and found a statistically significant reduction in all-cause mortality (OR 0.86, 95% CI 0.79–0.94). Fatal and non-fatal cardiovascular events, coronary heart disease events, and strokes were all meaningfully reduced. The review also found no evidence of serious harm.

Critics — and there are legitimate ones — point out that the absolute risk reductions in primary prevention are modest, particularly over short follow-up periods. A meta-analysis by Byrne and colleagues in JAMA Internal Medicine found absolute risk reductions of 0.8% for all-cause mortality and 1.3% for MI over the study period. That's real, but it's not dramatic. I think that framing misses something important: atherosclerosis doesn't wait for you to notice it, and cardiovascular risk compounds over decades. The question for a 36-year-old isn't "will this help me in the next five years?" It's "what does my vascular biology look like at 60 if I start now versus if I wait?"

Mendelian randomization studies — which use genetic variants as proxies for lifelong LDL exposure — suggest the cardiovascular benefit of lower LDL is substantially larger when it begins early in life. The biology of plaque formation is cumulative. Starting at 36 is not the same as starting at 60.

The meta-analytic consensus rests on a foundation of landmark individual trials worth naming, because the denialism movement has a habit of cherry-picking the negative ones.

WOSCOPS — the first major primary prevention RCT — enrolled over 6,500 men with elevated LDL and found a 3.3% absolute reduction in all-cause mortality with pravastatin (HR 0.88, 95% CI 0.79–0.99, p=0.03) over 20 years of follow-up. JUPITER randomized 17,800 apparently healthy adults with elevated hs-CRP and normal LDL to rosuvastatin vs. placebo; all-cause mortality fell significantly (HR 0.80, 95% CI 0.67–0.97, p=0.02). MEGA, conducted in a Japanese primary prevention population, found coronary heart disease events reduced by 33% with pravastatin (HR 0.67, p=0.01). HOPE-3 extended the benefit to an ethnically diverse intermediate-risk population with no prior CVD: rosuvastatin reduced the primary CV composite (CV death/MI/stroke) by 24% (HR 0.76, 95% CI 0.64–0.91; p=0.002). All-cause mortality was not significantly reduced in the 5.6-year trial. And PROSPER, in a mixed primary/secondary prevention population of older adults (age 70–82), showed coronary disease mortality fall by 24% (p=0.043).

There are also negative trials. ALLHAT-LLT found no all-cause mortality benefit for pravastatin over usual care (RR 0.99, p=0.88). That result matters and shouldn't be dismissed. But it is one trial — with methodological limitations including substantial cross-contamination between arms — against a robust meta-analytic signal from the CTT and Cochrane reviews. Individual trial heterogeneity is expected; that is precisely why we meta-analyze.

I debated whether to include this. But it felt dishonest not to — the whole premise of this article is physician vulnerability paired with clinical reasoning, and nothing is more concrete than actual lab work.

These are my actual lipid results, from 2018 to late 2025. Not anonymized population data from a trial in Perth. My labwork, from an outpatient portal in Oklahoma.

The pre-statin picture is instructive. My peak LDL was 127 mg/dL in May 2018 — "borderline" by the old framework that used 130 as the alarm threshold, unremarkable by the cultural standard of "you seem healthy." The 79 in mid-2019 was a motivated, vegetable-heavy stretch I couldn't sustain; by spring of 2020 it was back to 116. This is the natural history of diet-only LDL management in most people: transient, unstable, incomplete.

What the chart shows on the right side of that dividing line is not subtle. At my first post-statin check in December 2022: LDL 55 mg/dL — already below the 2026 ACC/AHA primary prevention target of 70. My most recent value is 41 mg/dL. My total cholesterol is currently 94. For reference, 94 is lower than the average American's LDL-C alone.

Full disclosure requires one more data point: I added ezetimibe 10 mg in November 2024. Ezetimibe works through a different mechanism than statins — it blocks intestinal cholesterol absorption rather than hepatic synthesis — and the IMPROVE-IT trial demonstrated that adding it to statin therapy reduced cardiovascular events further in high-risk patients. It is now generic and inexpensive. The lower values in the table — 31 and 41 mg/dL — reflect statin plus ezetimibe, not statin alone. I mention this not to complicate the argument, but because the premise of this article is transparency. The decision-making logic is the same: evaluate the evidence, accept a small daily inconvenience, act before the symptom announces itself.

I want to be careful not to turn personal lab data into a performance. The LDL number is not the point. The point is that I spent several years in the 100–127 range — well below the old "treat" threshold of 190, technically "normal" on most lab printouts — while atherosclerosis runs on a different accounting system than the reference range at the bottom of the page. Plaque doesn't wait for the alert flag.

I am now accumulating years at an LDL in the 31–55 range, starting in my mid-30s. If the Mendelian randomization literature is directionally right, that compounding will look very different at 65 than it would have on the trajectory I was on. That is not certainty. It is a reasonable bet on a low-cost, well-tolerated intervention with a 30-year evidentiary foundation.

Here is one of the most important and underappreciated facts in all of outpatient medicine: more than half of patients who start a statin abandon it within two years. The most commonly cited reason is side effects, predominantly myalgia — muscle pain. And yet, in blinded, placebo-controlled trials involving more than 80,000 participants, there is no excess in symptomatic side effects in patients taking statins compared to those taking placebo.

This paradox — real symptoms, no pharmacological signal — was elegantly resolved by the SAMSON trial, published in the New England Journal of Medicine in 2020. Sixty patients who had previously discontinued statins due to intolerable side effects were enrolled in an n-of-1, double-blind, crossover trial. Each participant received 12 one-month medication bottles — four containing atorvastatin 20 mg, four containing placebo, and four empty — in a randomized sequence. They reported daily symptom severity on a smartphone app.

The result was striking. Symptom scores were nearly identical during placebo and statin months — both significantly higher than no-tablet months. The calculated nocebo ratio was 0.90: ninety percent of the statin-attributed symptom burden was equally present on placebo. The act of taking a tablet — not the molecule inside — was driving the experience.

The clinical implication is profound: when patients are told these findings directly, half of them successfully restart statin therapy. The symptoms are real. The cause is not the statin. This is not gaslighting patients — it is giving them genuinely useful, empowering information.

I have shared SAMSON with dozens of patients in my practice over the past few years. It is one of the most practically useful single pieces of evidence I keep in my clinical toolkit. I have watched people who'd given up on statins revisit the decision with completely different framing — and stay on therapy.

This is where I'll ask you to hold two things simultaneously: a biologically plausible hypothesis and an honest accounting of what the randomized trial data actually shows.

The hypothesis is this: statins inhibit the mevalonate pathway, disrupting cholesterol synthesis in ways that may interfere with cancer cell proliferation, angiogenesis, and metastasis. Rapidly dividing cells — the hallmark of cancer — require more cholesterol for membrane synthesis. Statins also reduce prenylation of proteins like Ras and RhoA GTPases, altering downstream signaling in ways that can promote apoptosis and suppress tumor growth. This is real, well-characterized biology.

The observational literature is genuinely intriguing. An umbrella meta-analysis of 71 meta-analyses across 14 cancer sites found that statin use was associated with reduced likelihood of biliary tract cancer (33%), liver cancer (42%), gastric cancer (29%), colorectal cancer (9%), and several hematologic malignancies. These are not trivial numbers in isolation.

Dementia fear is real, and it's frequently invoked as a reason to either take or avoid statins — depending on who's talking. The evidence here has evolved meaningfully in the past year, and it deserves an honest accounting.

The foundational tension: observational studies consistently show statin users have lower dementia and Alzheimer's risk — a 2022 meta-analysis of 46 studies and over 7 million patients found a 20% reduction in all-cause dementia and a 32% reduction in Alzheimer's disease. Striking numbers, but plagued by the healthy user effect. Two large RCTs (Cochrane 2016, n=26,340) remain negative — statins given in late life to people at vascular risk do not prevent cognitive decline or dementia in trial conditions.

In 2026, a new entry into this debate: Novak et al. published a real-world data analysis using the TriNetX federated EHR network — over 125 million U.S. patients — and applied rigorous propensity score matching on 838,000 statin users and 838,000 matched non-users with dyslipidemia and no prior Alzheimer's diagnosis. They excluded diabetes, prior cerebrovascular disease, and known dementia confounders, and used a new-user design to minimize immortal time bias.

The 31% reduction in AD risk held up in a three-year lagged sensitivity analysis designed to exclude reverse causation — even excluding early events, statin users had a persistently lower hazard of AD (HR 0.68). Both lipophilic and hydrophilic statins showed protective effects compared to non-use; hydrophilic agents (rosuvastatin, pravastatin) showed slightly greater AD risk reduction than lipophilic agents in a head-to-head comparison.

The paper is intellectually honest about its limits: this is observational data, not a randomized trial. Residual confounding — particularly by unmeasured health behaviors and cognitive reserve — cannot be excluded. The authors do not claim causality, and neither will I. But this is the most methodologically rigorous observational evidence to date, and the effect size is consistent with the broader meta-analytic signal from 7+ million patients. It shifts the conversation.

My read: the RCT data is negative for late-life initiation, and that is the highest-quality signal. But the growing observational and RWD literature — now including a propensity score-matched cohort of 838,000 — raises a hypothesis worth taking seriously: that earlier, sustained exposure may protect vascular contributions to cognitive aging in ways a five-year late-life trial is simply not designed to detect. I am not taking a statin for dementia prevention. But I am less certain than I was that this trail goes nowhere.

A common concern — and a reasonable one — is whether statins for primary prevention stop making sense in very old age. The USPSTF currently calls the evidence insufficient for adults over 75. But a 2026 cohort study published in the Journal of the American Geriatrics Society adds meaningful data to this gap.

Lavon et al. studied 15,745 patients aged ≥80 years with no prior cardiovascular disease in the Clalit Health Services database in Israel — the largest HMO in the country, covering 4.6 million people. Over a mean follow-up of four years, statin use for primary prevention was associated with a 31% reduction in all-cause mortality (HR 0.69) and a 20% reduction in new coronary events (HR 0.80). No significant increase in myopathy, diabetes, or dementia was observed.

The critical finding — and the one I find most relevant for clinical counseling — is the continuity signal: benefits were not observed in patients who discontinued statins before age 80. Stopping erased the benefit. This aligns with the "lower for longer" principle: the protective effect is not a pill-by-pill transaction. It is the accumulated result of maintained LDL control over time.

This is a retrospective cohort study with the confounding limitations that come with that design. But it is 15,745 octogenarians with a four-year follow-up and time-varying exposure analysis to reduce immortal time bias. For a population the USPSTF explicitly calls evidence-insufficient, this is meaningful signal.

Today, it is essentially impossible to make a compelling cost-based argument against statins for primary prevention. Every major statin — atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin — is available as a generic. The cost at most pharmacies, with or without insurance, is under $10 per month, and frequently covered at zero copay on preventive drug formularies.

The Cochrane review explicitly noted that primary prevention with statins is likely to be cost-effective. Multiple pharmacoeconomic models have confirmed this finding across different risk strata and health systems. When the intervention costs less than a daily coffee, the denominator of the cost-effectiveness equation is basically zero.

This matters not just abstractly but clinically. In my practice — in obesity medicine, where cardiovascular risk is disproportionately elevated — cost has been the most common reason patients give for not filling a statin prescription. That barrier has largely dissolved. What remains is inertia, misperception, and an outdated cultural narrative that statins are "serious" drugs reserved for sick people.

A few people in my life — colleagues, family members, friends who read this newsletter — have asked me some version of: "Wait, you're on a statin? You seem fine." The unspoken assumption is that statins are for people who are already sick, already past some threshold of visible risk.

That framing is exactly backwards. Atherosclerosis is a slow, silent process. By the time it announces itself — by the time you have symptoms — you've often had decades of subclinical disease accumulation. The whole architecture of primary prevention is predicated on acting before the signal is obvious. The best time to lower LDL is when you don't need to yet.

I recognize I'm speaking from a position of unusual access — medical training, clinical experience, the ability to evaluate the literature and make an informed decision in conversation with my own prescriber. Most people don't have that. But I think the underlying logic is transferable: if your LDL is elevated, if you carry metabolic risk factors, if you're in mid-life and haven't had this conversation — it's worth having. Not because statins are right for everyone, but because the calculus is cleaner than the noise around it suggests.

I swallow those small pills every morning because the evidence earned my confidence. That's all this newsletter has ever been about.

REFERENCES

1. Cholesterol Treatment Trialists' (CTT) Collaboration. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590. doi:10.1016/S0140-6736(12)60367-5

2. Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;(1):CD004816. doi:10.1002/14651858.CD004816.pub5 [Updated 2022]

3. Howard JP, Wood FA, Finegold JA, et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment (SAMSON). J Am Coll Cardiol. 2021;78(12):1210–1221. doi:10.1016/j.jacc.2021.07.022

4. Wood FA, Howard JP, Finegold JA, et al. N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects. N Engl J Med. 2020;383(22):2182–2184. doi:10.1056/NEJMc2031173

5. Byrne P, Demasi M, Jones M, et al. Evaluating the Association Between Low-Density Lipoprotein Cholesterol Reduction and Relative and Absolute Effects of Statin Treatment: A Systematic Review and Meta-analysis. JAMA Intern Med. 2022;182(5):474–481. doi:10.1001/jamainternmed.2022.0134

6. Cholesterol Treatment Trialists' (CTT) Collaboration. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7(1):e29849. doi:10.1371/journal.pone.0029849

7. Chen W, Pu W, Liu F, et al. The association of statin therapy and cancer: a meta-analysis of 35 randomized controlled trials. Lipids Health Dis. 2023;22:192. doi:10.1186/s12944-023-01955-4

8. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev. 2016;(1):CD003160. doi:10.1002/14651858.CD003160.pub3

9. Olmastroni E, Molari G, De Beni N, et al. Statin use and risk of dementia or Alzheimer's disease: a systematic review and meta-analysis of observational studies. Eur J Prev Cardiol. 2022;29(5):804–814. doi:10.1093/eurjpc/zwab208

10. Wee J, Tan XR, Lai S, et al. Statin Initiation and Dementia Incidence in a Large Health Care System From 1997 to 2020. Neurology. 2023. doi:10.1212/WNL.0000000000213855

11. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet. 2019;393(10170):407–415. doi:10.1016/S0140-6736(18)31942-1

12. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study). Lancet. 2006;368(9542):1155–1163. doi:10.1016/S0140-6736(06)69472-5

13. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol lowering in intermediate-risk persons without cardiovascular disease (HOPE-3). N Engl J Med. 2016;374(21):2021–2031. doi:10.1056/NEJMoa1600176

14. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER). Lancet. 2002;360(9346):1623–1630. doi:10.1016/S0140-6736(02)11600-X

15. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care (ALLHAT-LLT). JAMA. 2002;288(23):2998–3007. doi:10.1001/jama.288.23.2998

16. Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation. 2016;133(11):1073–1080. doi:10.1161/CIRCULATIONAHA.115.019014

17. Ridker PM, Danielson E, Fonseca FAH, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER). N Engl J Med. 2008;359(21):2195–2207. doi:10.1056/NEJMoa0807646

18. Novak DA, Saleem N, Gerhardt PC, et al. Alzheimer's disease in patients prescribed statins: A real-world data analysis of U.S. patient health records. J Alzheimers Dis. 2026;110(3):1474–1489. doi:10.1177/13872877261424220

19. Lavon O, Hamodi W, Kassem S. Statin Therapy for Primary Prevention and Clinical Outcomes in Adults Aged 80 and Older: A Retrospective Comparative Cohort Study. J Am Geriatr Soc. 2026. doi:10.1111/jgs.70375

20. Salave S, Patel M, Patel B, et al. Statin use and risk of cancer: An umbrella meta-analysis. Ann Oncol Res Ther. 2023;3(1):14–31. doi:10.4103/aort.aort_34_22

21. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387–2397. doi:10.1056/NEJMoa1410489